In this issue we discuss whether clinicians know enough about the development of biosimilars to buy in, explore the biggest M&A trends in pharma and what to expect this year and consider the importance of disaccharides in the stabilisation of biologics. The journal also features articles on the fundamentals of contemporary supply chain management and how COVID-19 has impacted oncology drug development.
The rest of this content is restricted – login or subscribe free to access
Thank you for visiting our website. To access this content in full you’ll need to login. It’s completely free to subscribe, and in less than a minute you can continue reading. If you’ve already subscribed, great – just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- …And it’s all free!